radiopharmaceuticals

///radiopharmaceuticals

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer

  Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often left out of this conversation is safety, will the order we take our drugs or in what combination affect the our safety? We know that many of our new drugs cause cross-resistance to the next drug, however we rarely ask about the potential toxic effects [...]

Radium-223 When Given In Combinations May Improve Survival in mCRPC

As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough we can look forward to in the near future. In a recently released phase IIIb study of Radium-223 dichloride (Xofigo) that was given with concomitant medication, there was an improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) who also had [...]

Xofigo Without A Co-Pay For Men Who Are Uninsured or Who Have A Medical Policy That Doesn’t Cover Xofigo

I have been informed that it is now possible for men in need of the treatment Xofigo to obtain it without having to pay any co-pays.  The program that is making this possible is called Xofigo Access Services and is designed to make Xofigo available for men with a commercial medical insurance policy (not medicaid or medicare)  that doesn't cover the cost of Xofigo or who are uninsured. For more information about this program or to find out where Xofigo is available you can call 1-855-696-3446 and speak to a representative from 9:00 AM to 8:00 PM Monday through Friday. [...]

Skeletal Events and the Treatment of Men with Advanced Prostate Cancer

Many of our doctors are constantly vigilant about our developing skeletal related issues.   Having advanced prostate cancer and receiving treatment for this disease increases our odds of developing skeletal issues which affect both our quality of life and our mortality. Drugs like denosumab (Xgeva) and zoledronic acid (Zometa) are important in delaying the onset of skeletal related event complications, however neither of these drugs improve survival nor delay mortality. They both are beneficial and have an important role in delaying the complications of bone metastases in men with metastatic castrate resistant prostate cancer (mCRPC). The two new “super” ADT drugs [...]

スーパーコピーブランド ロレックススーパーコピー オメガスーパーコピー ブルガリスーパーコピー ブライトリングスーパーコピー カルティエスーパーコピー シャネル時計コピー IWCスーパーコピー フランクミュラースーパーコピー パネライスーパーコピー タグホイヤースーパーコピー ウブロスーパーコピー ガガミラノスーパーコピー ルイヴィトンスーパーコピー シャネルスーパーコピー エルメススーパーコピー グッチスーパーコピー ボッテガヴェネタスーパーコピー プラダスーパーコピー セリーヌスーパーコピー ロレックススーパーコピー ウブロスーパーコピー